New drugs for multiple sclerosis

Medical Letter on Drugs and Therapeutics

Volumn 54, Issue 1403, 2012, Pages 89-91

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AUBAGIO; BETA1A INTERFERON; DULOXETINE; ETHINYLESTRADIOL; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; LEVONORGESTREL; MITOXANTRONE; NATALIZUMAB; PIOGLITAZONE; PLACEBO; REPAGLINIDE; TERIFLUNOMIDE; TIZANIDINE; TYSBARI; UNCLASSIFIED DRUG; WARFARIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ALOPECIA; AMENORRHEA; ARTHRALGIA; ATRIOVENTRICULAR BLOCK; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; BORDERLINE HYPERTENSION; BRADYCARDIA; CARDIOTOXICITY; DEPRESSION; DIARRHEA; DRUG COST; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; FATIGUE; FLU LIKE SYNDROME; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; LETTER; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; LUNG FUNCTION; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PREGNANCY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA EDEMA; SEIZURE; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; THORAX PAIN; THYROID DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXIC EPIDERMAL NECROLYSIS; VIRUS INFECTION;

EID: 84870044589     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (14)

1. Interferon beta-1b (Extavia) for multiple sclerosis. Med Lett Drugs Ther 2010; 52:86.
2. Natalizumab (Tysabri) for relapsing multiple sclerosis. Med Lett Drugs Ther 2005; 47:13.
3. Natalizumab (Tysabri) returns. Med Lett Drugs Ther 2006; 48:76.
4. Oral fingolimod (Gilenya) for multiple sclerosis. Med Lett Drugs Ther 2010; 52:98.
5. A Shirani et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012; 308:247.
6. T Derfuss and L Kappos. Evaluating the potential benefit of interferon tretment in multiple sclerosis. JAMA 2012; 308;290.
7. HP Hartung et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicen-tre trial. Lancet 2002; 360:2018.
8. P O'Connor et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365:1293.
9. G Comi et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012; 366:1000.
10. Alemtuzumab (Campath) off-label for relapsing multiple sclerosis. Med Lett Drugs Ther 2009; 51:17.
11. JA Cohen et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet 2012 Nov 1 (epub).
12. AJ Coles et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet 2012 Nov 1 (epub).
13. R Gold et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367:1098.
14. RJ Fox et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367:1087.